MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.32−0.14 (-1.65%)
Close on Nov 18, 2026Market cap $799.08MP/E 11.7Yield –
MeiraGTx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MeiraGTx's operating income for the twelve months ending Jun 30, 2026 was $184.03M. For fiscal 2025 it was -$105.97M. The highest annual figure on record is -$31.68M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$105.97M | – |
| FY2024 | Dec 31, 2024 | -$164.21M | – |
| FY2023 | Dec 31, 2023 | -$137.06M | – |
| FY2022 | Dec 31, 2022 | -$116.36M | – |
| FY2021 | Dec 31, 2021 | -$72.76M | – |
| FY2020 | Dec 31, 2020 | -$62.55M | – |
| FY2019 | Dec 31, 2019 | -$58.27M | – |
| FY2018 | Dec 31, 2018 | -$78.10M | – |
| FY2017 | Dec 31, 2017 | -$31.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $244.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$40.82M | – |
| Q4 FY2025 | Dec 31, 2025 | $26.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$43.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$41.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.69M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.55M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.03M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.68M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.69M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.17M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.36M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.76M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.59M | – |
See a number that looks wrong?